FIG. 1

SEQ ID NO: 1 - Amino acid sequence of heavy chain of humanized anti-HER2 monoclonal antibody

EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSV
KGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSV
FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI
SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK
EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEW
ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP
GK

FIG. 2

SEQ ID NO: 2 - Amino acid sequence of light chain of humanized anti-HER2 monoclonal antibody

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSG
SRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSG
TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY
ACEVTHQGLSSPVTKSFNRGEC

FIG. 3



ST1616B/TDR (from 13-mo T-DM1 treated Pt)
HER2 IHC 3+
Cubic Millimeters
2000
1000
0
0
7
14
21
28
Day
Vehicle
T-DM1 10 mg/kg
ADC(1) 3 mg/kg
ADC(1) 10 mg/kg

FIG. 4



ST1360B/TDR (from 3-mo T-DM1 treated Pt)
HER2 IHC 3+
Cubic Millimeters
3000
2000
1000
0
Vehicle
T-DM1 10 mg/kg
ADC(1) 3 mg/kg
ADC(1) 10 mg/kg
0
7
14
21
28
Day

FIG. 5



a. ADC(1)
Mean
0.8
1.6
3.2
6.4
Concentration of DS-8201a (ug/mL)
Time (day)
b. 6.4 mg/kg
Mean
ADC(1)
Compound 1
Total Antibody
Compound 1: Payload of ADC(1)
Concentration (ng/mL)
Time (day)

FIG. 6




Decreased appetite
Nausea
Malaise
Vomiting
Alopecia
Constipation
Platelet count decreased
Blood cell count decreased
Neutrophil count decreased
Rash (total of each region)
Abdominal distension
Anaemia
AST increased
Influenza like illness
Headache
Malaise
Grade 1
Grade 2
Grade 3
0
10
20
30
40
50
60
70
80
90
100

FIG. 7



Prior T-DM1: Data by previous treatment of T-DM1

ADC(1): Data by ADC(1) who already have been treated with T-DM1

* 1 of 12 patient data who had no information of the best response on prior T-DM1 treatment is excluded

FIG. 8



HER2 IHC 3+ 2+ 1+ 0
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
#
#
$
Overall response was PD due to new lesion
$ Current IHC status although there were prior HER2 therapies
3.2 B
0.8 B
1.6 G
5.4 G
3.2 B
0.8 B
0.8 B
8.0 G
6.4 B
6.4 B
8.0 B
3.2 B
6.4 B
5.4 B
1.6 B
6.4 B
8.0 B
5.4 G
6.4 B
6.4 G
Dose (mg/kg)
B: Breast Cancer. G: Gastric Cancer

FIG. 9



Dose mg/kg
Tumor type
Current HER2 status
Week
6
12
18
24
30
36
42
0.8 mg/kg (N=3)
Breast Low
Breast Positive
Breast Positive
1.6 mg/kg (N=3)
Gastric Positive
Gastric Positive
Breast Positive
3.2 mg/kg (N=3)
Breast Negative
Breast Low
Breast Low
5.4mg/kg (N=4)
GE junction Positive
Breast Positive
Gastric Positive
Breast Positive
6.4mg/kg (N=6)
Gastric Positive
Breast Low
Breast Positive
Breast Positive
Breast Positive
Breast Positive
8.0mg/kg (N=3)
Breast Positive
Gastric Low
Breast Positive
PD
(ND)
PR
SD
PD
ND

FIG. 10



Tumor size: best% change from base line
%
80
60
40
20
0
-20
-40
-60
-80
-100
Breast cancer HER2 Positive
Breast cancer HER2 Low
Gastric cancer HER2 Positive
Gastric cancer HER2 Low
Others

FIG. 11



Breast cancer
Tumor size: change from base line
%
40
20
0
-20
-40
-60
-80
-100
0
10
20
30
40
50
Weeks
BC HER2 Positive
BC HER2 Low

FIG. 12



Gastric cancer
Tumor size: change from base line
%
40
20
0
-20
-40
-60
-80
-100
0
10
20
30
40
50
Weeks
GC HER2 Positive
GC HER2 Low

FIG. 13




Tumor size:
Maximum % change from baseline
40
20
0
-20
-40
-60
-80
-100
L C C L C S E C C L C L C S P L C C L C S S Ch P
IHC data
IHC 3+
IHC 2+
IHC 1+
IHC 0, —
Not measured
Unknown

FIG. 14


Tumor size:
% Change from baseline
60
40
20
0
-20
-40
-60
-80
-100
Colorectal
NSCLC
Salivary
Other
0
10
20
30
40
Weeks